A Phase IIb, double-blind, randomised, placebo-controlled parallel group study of the efficacy, safety and immunogenicity of oral RV3-BB Rotavirus Vaccine, administered as a neonatal schedule with birth (age 0-5 days) dose, 8-10 and 14-16 week doses or an infant schedule of 8-10 ,14-16 and 18-20 week doses.

Trial Profile

A Phase IIb, double-blind, randomised, placebo-controlled parallel group study of the efficacy, safety and immunogenicity of oral RV3-BB Rotavirus Vaccine, administered as a neonatal schedule with birth (age 0-5 days) dose, 8-10 and 14-16 week doses or an infant schedule of 8-10 ,14-16 and 18-20 week doses.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Rotavirus vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Therapeutic Use
  • Sponsors Biofarma
  • Most Recent Events

    • 05 Sep 2016 Status changed from recruiting to completed.
    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top